Results 231 to 240 of about 1,235,428 (322)

Insights Into the Antigenic Repertoire of Unclassified Synaptic Antibodies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We sought to characterize the sixth most common finding in our neuroimmunological laboratory practice (tissue assay‐observed unclassified neural antibodies [UNAs]), combining protein microarray and phage immunoprecipitation sequencing (PhIP‐Seq). Methods Patient specimens (258; 133 serums; 125 CSF) meeting UNA criteria were profiled;
Michael Gilligan, John R. Mills, Paulina Vargas, Naveen K. Paramasivan, Connie E. Lesnick, Eati Basal, Surendra Dasari, James P. Fryer, Shannon R. Hinson, Joseph Laporta, Amy Espinal, Dennis Fitzgerald, Carolina Garcia, Anna E. Morenkova, Paola Pergami, Anna Shah, Andrew Knight, Reghann LaFrance Corey, Vanda A. Lennon, Anastasia Zekeridou, Sean J. Pittock, Divyanshu Dubey, Andrew McKeon   +22 more
wiley   +1 more source

Lipid-lowering drug and complement factor H genotyping-personalized treatment strategy for age-related macular degeneration. [PDF]

iScience
Xue CC, Teo KYC, Tham YC, Li H, Thakur S, Sabanayagam C, Fan Q, Silver DL, Wang X, Cheung CMG, Wong TY, Chakravarthy U, Cheng CY, Nusinovici S.   +13 more
europepmc   +1 more source

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Common complement factor H polymorphisms are linked with periodontitis in elderly patients. [PDF]

J Periodontol, 2022
Salminen A, Pietiäinen M, Paju S, Sorsa T, Mäntylä P, Buhlin K, Sinisalo J, Pussinen PJ.   +7 more
europepmc   +1 more source

Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells [PDF]

, 2009
Simona Buelli, Mauro Abbate, Marina Morigi, Daniela Moioli, Cristina Zanchi, Marina Noris, Carla Zoja, Charles D. Pusey, Peter F. Zipfel, Giuseppe Remuzzi   +9 more
openalex   +1 more source

Fluid and Neuroimaging Biomarkers in Microgliopathy Colony‐Stimulating Factor‐1 Receptor‐Related Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela, Madison Reeves, Karen Jansen‐West, Judith Dunmore, Yuping Song, Audrey Strongosky, Sunil Gandhi, Gilana Pikover, Matt Blurton‐Jones, Robert C. Spitale, Erik H. Middlebrooks, Leonard Petrucelli, Mercedes Prudencio, Zbigniew K. Wszolek   +13 more
wiley   +1 more source

Elevated factor H–related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy [PDF]

, 2017
Agustín Tortajada, Eduardo Gutiérrez, Elena Goicoechea de Jorge, Jaouad Anter, Alfons Segarra, Mario Espinosa, Miquel Blasco, Elena Román, Helena Marco, Luís F. Quintana, J Ruiz Gutiérrez, Sheila Pinto, Margarita López‐Trascasa, Manuel Praga, Santiago Rodrı́guez de Córdoba   +14 more
openalex   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial. [PDF]

Nat Commun
Clarke JM, Simon GR, Mamdani H, Gu L, Herndon JE, Stinchcombe TE, Ready N, Crawford J, Sonpavde G, Balevic S, Nixon AB, Campa M, Gottlin EB, Li H, Saxena R, He YW, Antonia S, Patz EF.   +17 more
europepmc   +1 more source

Table S2 from Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103

Ryan T. Bushey, Ruchi Saxena, Michael J. Campa, Elizabeth B. Gottlin, You‐Wen He, Edward F. Patz   +5 more
openalex   +1 more source